FibroBiologics ships third CYWC628 batch to Australia for Phase 1/2 diabetic foot ulcer trial

Reuters2026/08/27 12:30

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

FibroBiologics released a third batch of CYWC628 for its Phase 1/2 diabetic foot ulcer trial, supporting continued dosing at Australian sites.
CYWC628 is a topical allogeneic fibroblast cell therapy being tested alongside standard care versus standard care alone.
Results have not been presented; statistically significant interim primary outcome data are expected in the second half of 2026.
Early progress in the ongoing study was described as encouraging, pointing to potential clinical benefit if confirmed in interim readouts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608270830PR_NEWS_USPR_____DA34861) on August 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

FibroBiologics ships third CYWC628 batch to Australia for Phase 1/2 diabetic foot ulcer trial

You may also like

Crypto prices